TAYSHA GENE THERAPIES INC (TSHA) Stock Income Statement
NASDAQ:TSHA - Nasdaq - US8776191061 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.22M | 8.33M | 15.45M | 2.50M | 0.00 | |||
| Operating Expenses | 90.94M | 94.95M | 86.83M | 128.53M | 173.27M | |||
| Research and Development | 60.91M | 66.00M | 56.78M | 91.17M | 131.94M | |||
| Selling, General, and Administrative Expenses | 30.03M | 28.95M | 30.05M | 37.36M | 41.32M | |||
| Operating Income | -83.71M | -86.62M | -71.37M | -126.03M | -173.27M | |||
| Interest Income/Expense | 6.48M | 6.84M | -1.43M | -3.55M | -1.26M | |||
| Other Income/Expense | -4.70M | -4.68M | -36.30M | -20.00K | 0.00 | |||
| Non Recurring Items | N/A | -4.84M | -2.46M | -36.42M | N/A | |||
| Income Before Taxes | -86.77M | -89.30M | -111.57M | -166.01M | -174.52M | |||
| Net Income | -86.77M | -89.30M | -111.57M | -166.01M | -174.52M | |||
| EBITDA | -82.51M | -85.38M | -70.00M | -124.86M | -172.78M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | |||
| Non GAAP EPS | -0.34 | -0.36 | 0.13 | -3.13 | -4.63 | |||
| Statistics | ||||||||
| Profit Margin | -1201.08% | -1071.62% | -722.06% | -6640.40% | N/A | |||
| Operating Profit Margin | -1158.80% | -1039.49% | -461.94% | -5041.20% | N/A | |||
All data in USD